Drug Search Results

ICAM-1

Alternative Names: icam-1
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ICAM-1

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
EDIPE	N/A	Not yet recruiting	Hypertension\|Pregnancy Outcomes\|Pre-Eclampsia	2026-05-01
ChiCTR1900027080	N/A	Recruiting	GNE Myopathy\|Ventricular Dysfunction, Left\|Diabetes Complications\|Coronary Disease\|Heart Failure, Diastolic\|Hypertension\|Dyspnea\|Heart Failure, Systolic\|Heart Failure, Chronic	2022-12-31

Recent News Events

Date	Type	Title
05/15/2024	PubMed	Whole genome sequencing based analysis of inflammation biomarkers in the Trans-Omics for Precision Medicine (TOPMed) consortium.
05/15/2024	PubMed	Effects of Nox4 upregulation on PECAM-1 expression in a mouse model of diabetic retinopathy.
05/02/2024	PubMed	Rapid Assessment of Biomarkers on Single Extracellular Vesicles Using 'Catch and Display' on Ultrathin Nanoporous Silicon Nitride Membranes.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions